Dmitry Genkin

In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ILTS 2023 Congress on Liver Transplantation, held in Rotterdam where he presented a Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG continues to present the latest work across the globe, presenting at conferences in Berlin, Rotterdam, Athens, and Milan Read More »

In the beginning of March, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG at BTS conference, held in Edinburgh where he presented a recent Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG presented at NHSBT Joint Congress, held by British Transplantation Society Read More »

At the end of February, Andrew Aswani, MD, PhD (Santersus AG Chief Medical Officer) participated in the 10th Annual UC San Diego Essentials & Advances in Apheresis Therapies. Dr. Aswani had the opportunity to share current success regarding Santersus and our development of the selective therapeutic cell-free DNA/NET apheresis device to a large audience of …

Santersus AG presented at Apheresis Conference at the University of California San Diego Read More »

A study, published on Jan. 20 in PNAS, identifies cell-free DNA as a highly versatile analyte for monitoring of the most important complications of hematopoietic cell transplantation: Graft-Versus-Host Disease, infection, graft failure and disease relapse. Hematopoietic cell transplantation is the gold standard treatment for many blood disorders, including blood cancers. Nonetheless, frequent post-transplant complications limit …

Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation Read More »

Santersus AG is proud to be recognized as a top innovator and to be granted a presentation slot at the transCampus Partnership 10 year Anniversary Event in London on February 13, 2023. The transCampus partnership, which is overseen by joint Dean, Professor Stefan Bornstein includes joint professorships, administrative structures and training programmes for students from the …

Santersus AG Presented at transCampus Partnership Event in London Read More »

Physiology and biological impact of removing circulating cell-free DNA/Neutrophil Extracellular Trap (cfDNA/NET) on modifying lung injury at University of Edinburgh on FindAPhD.com In critically ill patients, cell free DNA (cfDNA), a danger signal capable of initiating intense innate immune responses, is measurable in circulation. Higher levels of cfDNA in circulation is associated with greater inflammatory …

Santersus AG is excited to announce the commencement of its PhD program with the University of Edinburgh. Read More »

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics …

Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA Read More »

It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent inflamm-ageing and slow down functional decline in the elderly.